Dexcom on Thursday reiterated its full-year revenue guidance after reporting quarterly results that topped Wall Street expectations, citing healthy demand for its continuous glucose monitors (CGMs).
The company said it remains confident in its forecast for annual revenue in the range of $5.16 billion to $5.25 billion. Analysts, based on data compiled by LSEG, expect the company to generate $5.23 billion for the year.
For the quarter, Dexcom recorded revenue of $1.19 billion, a 15% increase from the same period a year earlier, and slightly above the analysts' consensus of $1.18 billion. On an adjusted basis, the company reported earnings of $0.56 per share, outperforming expectations of $0.47 per share.
Despite the beat, Dexcom's shares fell 4.3% in after-hours trading.
Product and platform progress
During the quarter, Dexcom expanded the U.S. launch of its Dexcom G7 15 Day sensor. It also introduced new meal-logging capabilities on the Stelo platform and released clinical data indicating benefits for people with type 2 diabetes who are not using insulin.
The Stelo device, an over-the-counter CGM intended for adults not on insulin, represents Dexcom's effort to move into a broader consumer health segment. The company is positioning Stelo to serve people with type 2 diabetes as well as individuals who monitor blood glucose levels to manage their health.
Market environment
Industry dynamics cited by the company and observers include rising awareness of diabetes management, expanding insurance coverage for CGMs and a consumer shift away from finger-prick testing toward continuous, noninvasive monitoring. These trends have helped lift demand for CGMs but also intensified competition among established players, including Dexcom, Medtronic and Abbott Laboratories.
Dexcom said demand for its CGM devices remained healthy during the quarter, and the company pointed to the recent product rollouts and platform updates as part of its growth strategy in both clinical and consumer channels.
Implications and outlook
By maintaining its $5.16 billion to $5.25 billion revenue range, Dexcom signaled confidence in its current trajectory while acknowledging a competitive and evolving market. The company highlighted incremental product features, expanded sensor availability and new clinical findings as contributors to sustained demand.